Latest Delivery Technology News

Page 1 of 4
Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.
Ada Torres
Ada Torres
12 Feb 2026
PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.
Ada Torres
Ada Torres
2 Feb 2026
Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.
Ada Torres
Ada Torres
2 Feb 2026
EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.
Ada Torres
Ada Torres
30 Jan 2026
Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.
Ada Torres
Ada Torres
29 Jan 2026
Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.
Ada Torres
Ada Torres
16 Jan 2026
Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.
Victor Sage
Victor Sage
12 Jan 2026
Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.
Ada Torres
Ada Torres
5 Jan 2026
CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.
Victor Sage
Victor Sage
8 Dec 2025
Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.
Ada Torres
Ada Torres
3 Dec 2025
Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.
Ada Torres
Ada Torres
25 Nov 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.
Ada Torres
Ada Torres
3 Nov 2025